Login to Your Account


Potential $340M Partnership

Sickle Cell Crisis Drug Lands Pfizer Deal for GlycoMimetics

By Jennifer Boggs


Wednesday, October 12, 2011
Privately held GlycoMimetics Inc. landed its first big pharma partnership, licensing rights to pan-selectin antagonist GMI-1070 to Pfizer Inc. for further development in the orphan indication of sickle cell crisis, as well as other indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.